At a glance
ClinicalIndex Comparison RecordN/ACompleted· 25 enrolled
Drug / intervention
Monoviscdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Study of a Single Injection Cross-linked Sodium Hyaluronate (MONOVISC) to Provide Symptomatic Relief of Osteoarthritis of Shoulder Joint
In Brief
A clinical study evaluating Monovisc for Osteo Arthritis Shoulders. Completed, enrolled 25 participants across 4 sites in 2 countries.
Detailed Summary
Obtain real world, post market data to confirm the clinical improvement and safety in patients treated with a single injection of MONOVISC for the symptomatic relief of osteoarthritis in the shoulder joint.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteo Arthritis Shoulders
CountriesCzechia, Poland
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartDec 2019
First PostedDec 2019
Primary CompletionFeb 2021
Study CompletionMar 2021
TodayJul 2026
First PostedDec 18, 2019
Enrollment StartDec 17, 2019
Primary CompletionFeb 26, 2021
Study CompletionMar 30, 2021
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 6.5 years ago
Interventions
Monoviscdevice
A chemically cross-linked sodium hyaluronate supplied as a 4 mL unit dose in a 5 mL glass syringe.